US Patent 6,779,468: Scope, Claims, and US Landscape for Parenteral Ferric Pyrophosphate to Treat Iron Deficiency
What does US 6,779,468 claim, at the method-of-use level?
US 6,779,468 is directed to a method for treating iron deficiency using parenteral ferric pyrophosphate. The claim set is narrow in carrier chemistry and broad in treatment intent and administration modality.
Claim set (as provided)
Claim 1 (core method claim)
- “A method for treating iron deficiency comprising parenterally administering … an effective amount of ferric pyrophosphate, so that bioavailable iron is safely and effectively administered.”
Claim 2 (route-dependent limitation)
- Method of claim 1 where the route is selected from:
- subcutaneous
- intramuscular
- transdermal
- intravenous
Claim 3 (specific route)
- Method of claim 2 where route is intravenous.
Claim 4 (specific dosing rate)
- Method of claim 2 where ferric pyrophosphate is administered at about 40 mg per hour.
Practical claim scope implications
- Active ingredient scope: The claims are anchored to ferric pyrophosphate as the iron source. No other iron complex is claimed in the provided text.
- Use scope: “Iron deficiency” is the treatment endpoint. The independent claim does not limit to a population (e.g., CKD, pregnancy, pediatric, oncology-related anemia) in the text provided.
- Route scope: Claim 2 explicitly expands coverage beyond intravenous to multiple parenteral routes, including transdermal (even though “parenteral” typically implies non-oral systemic routes; the claim text itself includes transdermal in the route selection list).
- Dose-rate scope: Claim 4 adds a compliance hook for litigation and design-around strategy: a dosing regimen of ~40 mg/hour is singled out.
How strong is claim enforceability if you are designing around the administration route or dosing?
US 6,779,468 has a classic stratified claim structure: an independent method claim (Claim 1), a route-dependent claim (Claim 2), a route-narrow dependent claim (Claim 3), and a dosing-rate dependent claim (Claim 4).
Route design-around matrix (based on the claim language you supplied)
- If an infringing product uses ferric pyrophosphate and targets “iron deficiency,”
- Intravenous use is squarely covered (Claim 3).
- Use via subcutaneous or intramuscular also remains within Claim 2.
- The claim text also lists transdermal as a permitted route under Claim 2.
- If you remove ferric pyrophosphate (different active ingredient)
- None of the provided claim language covers substitute iron complexes.
- If you use ferric pyrophosphate but treat a different indication
- The independent claim is limited to “treating iron deficiency.” Products focused on other iron homeostasis targets without a “treating iron deficiency” framing create potential non-infringement arguments.
Dosing design-around matrix
- Claim 4 is specifically “about 40 mg per hour.”
- A regimen that consistently stays outside “about 40 mg per hour” may avoid Claim 4 while still risking Claim 1-3 if the route and active ingredient are otherwise met.
- If a product’s labeling or protocol uses intravenous ferric pyrophosphate at a different infusion rate, Claim 4 becomes less relevant as a cause of action, but Claims 1-3 still remain live.
Where does US 6,779,468 sit in the ferric salt / iron deficiency patent landscape?
This patent belongs to the broader “parenteral iron” space, which typically splits into:
- New iron complexes (composition)
- Manufacturing / stability / formulation (process)
- Administration methods (routes, dosing regimens)
- Indication-specific methods (patient populations, endpoints)
US 6,779,468 is a method-of-treatment patent that centers on:
- Iron deficiency
- Parenteral ferric pyrophosphate
- Route selection
- A specific infusion rate (about 40 mg/hour)
How competitors typically attack such claims
For method-of-use patents anchored to a specific compound, typical competitive and litigation strategies include:
- Switching the iron complex (avoids ferric pyrophosphate limitation).
- Avoiding the specific dosing-rate “anchor” (to neutralize Claim 4).
- Avoiding “treating iron deficiency” language in protocols and documentation (to challenge the treatment endpoint, especially where patients have borderline or non-labeled states).
- Using non-listed routes or administration formats (here Claim 2 lists multiple routes, so route is not an easy design-around unless the protocol uses a route not contained in the list).
What the claim structure signals for enforcement
- Claim 1 provides the most durable path for enforcement because it does not lock to a particular route or infusion rate beyond “parenterally.”
- Claim 2 and Claim 3 are “coverage expansions” for route behavior, not separate active ingredient concepts.
- Claim 4 is a narrower regimen hook that can support stronger infringement narratives when a protocol matches the infusion rate.
Which products or technologies are most likely to intersect with this claim set?
Given only the claim text you provided, the most direct overlap requires two conditions:
- The product contains ferric pyrophosphate (as administered).
- The product is used to treat iron deficiency with a parenteral route covered by the claim set.
Highest-intersection scenario
- Intravenous ferric pyrophosphate administered with infusion regimens in the neighborhood of 40 mg/hour.
- This scenario can implicate Claims 1, 2, 3, and 4 simultaneously.
Next-highest intersection scenario
- Intravenous or subcutaneous/intramuscular ferric pyrophosphate used to treat iron deficiency, but infusion rate is not near 40 mg/hour.
- This tends to target Claims 1-3 while weakening Claim 4.
Lower intersection scenario
- Ferric pyrophosphate used, but not for “treating iron deficiency” in the relevant patient context, documentation, or protocol framing.
- This can reduce enforceability against a method-of-treatment claim.
How should you map the patent to US regulatory and label-driven behavior?
Method patents often become actionable based on how dosing and administration instructions are implemented in routine care. US 6,779,468 includes explicit route and infusion-rate language that can be mirrored in:
- healthcare provider administration protocols
- infusion pump settings
- pharmacy preparation instructions
- label-based or guideline-based dosing schedules (where they align with the “about 40 mg/hour” language for intravenous use)
Because Claim 2 includes multiple routes, enforcement can focus on clinical administration choices, not only on intravenous infusion practices.
What does the claims’ internal logic mean for claim construction risk?
Even without prosecution history, the provided claim text indicates:
- “Parenterally administering” is the gating concept.
- Claim 2 further defines a permitted route set that includes subcutaneous, intramuscular, transdermal, and intravenous. This reduces ambiguity on route scope within those categories.
- Claim 1 does not define “effective amount,” leaving room for broad interpretation. Claim 4 then narrows to a specific rate, reducing ambiguity for that regimen.
Competitor landscape: how to position a new entry against this patent family risk
To evaluate patent landscape risk in the US, you typically screen by:
- molecule identity (ferric pyrophosphate vs alternatives)
- route used (IV, SC, IM, transdermal)
- regimen (especially infusion rate targets)
- indication framing (iron deficiency treatment)
Fast screening checklist tied to US 6,779,468
- Is the administered active species ferric pyrophosphate?
- Is the treatment purpose documented as treating iron deficiency?
- Is the administration parenteral, and is it within the route list in Claim 2?
- If intravenous, does the administration schedule run near 40 mg/hour?
- Is the product’s clinical routine protocol consistent with those conditions?
What is the most likely “center of gravity” for infringement theories?
Based on the dependency chain:
- If an accused administration is intravenous and uses ferric pyrophosphate to treat iron deficiency, Claims 1 and 3 are the first target.
- If the dosing rate aligns with about 40 mg/hour, Claim 4 can become a high-value hook.
- If the administration is SC/IM (still covered by Claim 2) and is used to treat iron deficiency with ferric pyrophosphate, Claim 2 becomes the principal dependent claim.
Key Takeaways
- US 6,779,468 is a method-of-treatment patent centered on parenteral ferric pyrophosphate for iron deficiency.
- Coverage expands by route via Claim 2 to subcutaneous, intramuscular, transdermal, and intravenous, and is further narrowed to intravenous in Claim 3.
- The most specific regimen point is about 40 mg per hour in Claim 4, creating a dosing-rate compliance target.
- The claim set is most exposed when an accused regimen uses ferric pyrophosphate and implements parenteral administration within the listed routes to treat iron deficiency, especially when intravenous dosing is near 40 mg/hour.
FAQs
1) Does the patent claim the composition of ferric pyrophosphate?
No. Based on the provided claims, it claims a method of treating iron deficiency using ferric pyrophosphate by parenteral administration.
2) Which administration routes are explicitly covered?
Claim 2 lists subcutaneous, intramuscular, transdermal, and intravenous as covered route selections.
3) Is intravenous administration covered even without matching the 40 mg/hour rate?
Yes. Intravenous falls under Claim 3, and Claim 4 is a narrower dosing-rate limitation.
4) What is the most specific dosing element in the claims?
Claim 4 specifies administration at about 40 mg per hour.
5) What is the primary design-around lever?
Avoid using ferric pyrophosphate as the administered iron source for treating iron deficiency; otherwise, route and dosing still fall within the claim framework if ferric pyrophosphate is used.
References
[1] User-provided claim text for US Drug Patent 6,779,468 (claims 1-4).
